Skip to main navigation

Overview
Shareholder Information
Events & Presentations
News
Corporate Governance
IR Contact
- Email Alerts
- Contact IR

News

News

Year

May 24, 2022

Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022

PDF Version

May 9, 2022

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

PDF Version

NL

May 6, 2022

Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022

PDF Version

NL

May 5, 2022

Oxurion to Participate in Upcoming Conferences

PDF Version

May 3, 2022

Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

PDF Version

April 29, 2022

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

PDF Version

NL

April 11, 2022

Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

PDF Version

April 1, 2022

Oxurion Announces Extraordinary and Annual Shareholders’ Meetings

PDF Version

NL

March 30, 2022

Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA

PDF Version

NL

March 28, 2022

Oxurion to Participate in Needham Virtual Healthcare Conference

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Next page
Last page

Displaying 31 - 40 of 52

Section Title

Who We Are
THR-149
News & Events
Let’s Talk

Connect with Us

LinkedIn
Twitter

Ⓒ2022 Oxurion NV. All rights reserved.